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CHEN AND LAU

Recent Advances in Antithrombin Therapy for Acute Coronary
Syndromes
WAI-HONG CHEN1, CHU-PAK LAU2
From Division of Cardiology, Department of Medicine, Ruttonjee Hospital1 and Queen Mary Hospital2, Hong Kong
SAR, China

CHEN AND LAU: Recent Advances in Antithrombin Therapy for Acute Coronary Syndromes. Unstable angina
and acute myocardial infarction are leading causes of hospital admissions worldwide. Following the initiating event
of atherosclerotic plaque rupture, activation of the coagulation cascade plays an important role in mediating local
thrombosis. Novel antithrombotic agents have recently been developed and applied in clinical practice. The direct
antithrombins have the advantage of inhibiting both fluid-phase and clot-bound thrombin. Despite a sound theoretical
basis, the prototypical agent hirudin has been demonstrated to be only equivalent to unfractionated heparin as
adjunctive therapy to thrombolysis in ST-elevation myocardial infarction. Although showing a better efficacy than
unfractionated heparin in unstable angina/non-Q wave myocardial infarction, hirudin causes more major bleeding
complications. Low-molecular-weight heparins have the advantages of a better bioavailability, longer half-life and
dose-independent clearance, making subcutaneous administration possible and monitoring unnecessary. Enoxaparin
has been proven to be superior to unfractionated heparin in two large randomised trials of unstable angina/non-Q
wave myocardial infarction while equivalence is demonstrated for other low-molecular-weight heparins. A higher
anti-Xa:anti-IIa ratio may explain the varying efficacy. In the near future low-molecular-weight heparins and newer
antithrombin agents may replace unfractionated heparin in the management of acute coronary syndromes as ongoing
clinical trials further define their roles. (J HK Coll Cardiol 1999;7:109-118)

Introduction
Every year more than four million patients are
admitted to hospitals worldwide with the diagnosis of
unstable angina (UA) or acute myocardial infarction
(MI). The initiating event is rupture of an atherosclerotic
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plaque followed by local thrombosis. The classic view
of the coagulation cascade postulated that two
independent pathways converged on the activation of
factor X. The intrinsic pathway (initiated by contact
activation) and the extrinsic pathway (activated by tissue
factor) are now conceived to be a highly integrated
complex system, with release of tissue factor playing
the integral role. In vivo, activation of factor VII by
tissue factor is the key step in the initiation of
coagulation and the intrinsic pathway is not considered
important. Tissue factor, a protein found on the
membrane of many different cell types, is not normally
exposed to blood elements but is expressed following
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injury to activated endothelial cells. It is also found in
the subendothelial matrix that is exposed after intimal
injury.
Figure 1 shows a simplified diagram of key steps
involved in activation of the coagulation cascade via
the tissue factor pathway. With rupture or erosion of a
vulnerable plaque, tissue factor is exposed and factor
VII is activated. The tissue factor-VIIa complex leads
to the activation of factor X. Activated factor X is a
critical component of the coagulation system because
it participates in the assembly of the prothrombinase
complex. A single molecule of factor Xa can lead to
the production of multiple molecules of thrombin, which
is the major component of haemostasis in both the fluid
phase and the clot-bound phase.
In addition to the coagulation cascade being
activated, platelets adhere to the subendothelial matrix
at the site of plaque rupture, release thromboxane A2,
serotonin, and adenosine diphosphate, and amplify the
generation of thrombin.1 Platelet aggregates form as the
activated state of the glycoprotein IIb/IIIa receptor is
expressed on the surface of activated platelets.
Multivalent ligands such as fibrinogen bind to the
glycoprotein IIb/IIIa receptors on multiple platelets,
providing cross-linking and propagation of a platelet
aggregate.
When coronary blood flow is reduced
significantly, patients experience ischaemic discomfort.
Complete occlusion of the culprit vessel results in ST
segment elevation on the electrocardiogram, and most

of these patients ultimately develop a Q-wave MI
(QWMI). A small proportion of patients may sustain
only a non-Q-wave MI (NQWMI). If the obstructing
thrombus (fibrin mesh and platelet aggregates) is not
totally occlusive, the obstruction is only transient or a
rich collateral network is present, no ST segment
elevation is seen. The majority of such patients are
diagnosed as having UA or, if a serum cardiac marker
indicative of myocardial necrosis is detected (e.g.
creatine kinase MB, troponin I or T), as having a
NQWMI. A minority of patients who initially present
without ST segment elevation might ultimately develop
a Q-wave MI. The various presentations from UA
through NQWMI and QWMI are collectively referred
to as the acute coronary syndromes (ACS; figure 2).2
While avoidance of smoking, improved diet and
exercise, treatment of hypertension, use of aspirin and
management of dyslipidaemia will reduce the incidence
of ACS, medical treatment to interrupt the cascade
towards thrombin formation constitutes a major advance
in cardiology. The role of novel antiplatelet agents has
recently been highlighted.3 The purpose of the present
article is to review the role of drugs on the coagulation
cascade.

Antithrombin therapy for acute coronary
syndromes
Thrombin is an important molecule in the ACS

X
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Figure 1. Activation of the coagulation cascade
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because of its extensive procoagulant and prothrombotic
actions.4 In addition to catalyzing the transformation of
soluble fibrinogen to fibrin monomers and activating
factor XIII to produce cross-linked fibrin, thrombin
promotes clot formation by activating factors V and
VIII. It is also one of the most potent agents for platelet
adhesion, activation, and aggregation. In vessels with a
diseased endothelium, thrombin promotes the release
of the vasoconstrictor endothelin-1. Thrombin also
potentiates the proliferative effects of multiple growth
factors and is a key mediator of early smooth muscle
cell proliferation following arterial injury. Previous
investigations have shown that the effects of thrombin
can be neutralised by either direct or indirect inactivation
and by inhibition of thrombin production via the
intrinsic or extrinsic limbs of the coagulation cascade.4
Because of thrombin's central role in the
pathogenesis of UA and acute MI, antithrombin therapy
is applicable across the entire spectrum of ACS. The
standard agent used in clinical practice is heparin.
Unfractionated heparin (UFH) is a glycosaminoglycan,
consisting of chains of alternating residues of Dglucosamine and uronic acid. 5 Clinically available
preparations of UFH are heterogeneous mixtures of
polysaccharide chains ranging in molecular weight from
3,000 to 30,000 daltons. UFH exerts its anticoagulant
effect by activating antithrombin III (AT III). The
mechanism involves binding to a unique
pentasaccharide sequence that is randomly distributed

along the heparin chains. The binding results in a
conformational change in AT III, accelerating its ability
to inhibit thrombin and factor Xa by about a thousandfold.5
Despite familiarity to many clinicians, UFH has
the following disadvantages: (1) a variable anticoagulant
effect (requiring frequent activated partial
thromboplastin time [aPTT] monitoring), (2)
neutralization by platelet factor 4, (3) less effective
inhibition of clot-bound versus fluid-phase thrombin,
and (4) the potential to cause thrombocytopenia
and heparin-induced thrombocytopenia syndrome
(HITS).5-7
Several novel antithrombin regimens have been
proposed. One involves using a closed-loop feedback
system that automatically measures the patient's aPTT
and adjusts an infusion of UFH to maintain the level of
anticoagulation in the target aPTT range. Alternative
approaches have focused on new pharmacologic agents.
The agents most extensively investigated in clinical
trials include the AT III-independent (or direct)
antithrombins and the low-molecular-weight heparins
(LMWHs).

Direct antithrombins
Direct antithrombins are novel anticoagulants that
inhibit thrombin directly without requiring the cofactor

Ischaemic chest discomfort at rest

ST-segment
elevation

No ST-segment
elevation

Unstable

* = Positive serum
cardiac marker

Non-Q-wave

Q-wave

Figure 2. Acute coronary syndromes
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AT III. Although a variety of direct antithrombins have
been identified, those that have undergone clinical
investigation to date include hirudin, hirulog,
argatroban, efegatran, and inogatran.8-10 All of the direct
antithrombins exhibit a concentration-dependent
anticoagulant effect. Because of their tight binding to
thrombin, hirudin and hirulog are virtually irreversible
thrombin inhibitors while argatroban, efegatran, and
inogatran are reversible inhibitors. Although in-vitro
differences among the various direct antithrombins have
been identified (e.g., binding characteristics to thrombin,
ability to inhibit thrombin generation), it is unclear
whether these differences will have any important
impact on the clinical use of the direct antithrombins.11
Hirudin is a prototype of the direct antithrombins
and has been extensively studied. The carboxy terminus
of hirudin binds to the substrate recognition site on
thrombin, while the amino terminus inhibits the catalytic
center of thrombin.8 Since clot-bound thrombin is less
effectively inhibited by UFH (because the attachment
of fibrin to the fibrin-binding domain makes the heparinbinding domain inaccessible, figure 3), it has been
suggested that the direct antithrombins have a greater
ability than UFH to inhibit both fluid-phase and clotbound thrombin.12 This concept has been referred to as
the "thrombin hypothesis" and was the inspiration for
several randomised controlled trials.

Trials of direct antithrombins as
adjunctive therapy to thrombolysis in
ST-segment-elevation ACS
Based on the initial favorable observations in the
phase-II Thrombolysis in Myocardial Infarction (TIMI)
5 and 6 trials, 13-14 several phase-III trials of direct
antithrombins as adjunctive therapy to thrombolysis
were undertaken. 15-17 Table 1 summarises the main
features of the TIMI 9A, Global Use of Strategies to
Open Occluded Coronary Arteries (GUSTO) IIa, and
r-hirudin for Improvement of Thrombolysis (HIT-III)
trials. TIMI 9A and HIT-III focused on patients with
ST-segment-elevation MI, and GUSTO IIa enrolled
patients with clinical presentations across the ACS
spectrum. A feature common to all three trials was that
they were stopped prematurely because of unacceptable
rates of major haemorrhages, particularly intracranial
hemorrhage. Possible reasons include high levels of
anticoagulation in both the heparin and hirudin groups
in TIMI 9A and GUSTO IIa, a low estimate of the
haemorrhagic risk at the doses of hirudin used in the
previous phase-II trials, and attempts to push the heparin
dose to achieve higher aPTT levels to prevent
reocclusion of successfully reperfused vessels.14 As a
result of these findings, the doses of both heparin and
hirudin were reduced and the TIMI 9B and GUSTO IIb

Figure 3. Comparative mechanisms of action of
heparin and hirudin. Heparin inactivates fluid-phase
thrombin via the action of AT III, but is ineffective for
clot-bound thrombin as the heparin-binding domain
is inaccessible. Hirudin binds to the substrate
recognition site of thrombin, and is active for both fluidphase and clot-bound thrombin.
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trials were undertaken.
In TIMI 9B, patients were treated with either
tissue plasminogen activator (tPA) or streptokinase (SK)
at the physician's discretion and received a 96-hour
infusion of either hirudin or heparin. 18 The rate of
development of the primary endpoint (death, recurrent
nonfatal MI, or severe congestive heart failure or
cardiogenic shock by 30 days) was 11.9% in the 1,491
patients in the heparin group and 12.9% in the 1,511
patients in the hirudin group (p = NS). In addition, there
was no significant difference in the secondary endpoint
of death and recurrent nonfatal MI.
In the GUSTO IIb trial, patients were stratified
into those presenting with ST-segment elevation (N =
4,131) or without ST-segment elevation (n = 8,011).
Hirudin or heparin was infused for a minimum of 3 days
and a maximum of 5 days. The primary endpoint (death
or nonfatal MI at 30 days) occurred in 9.8% of the
heparin group and 8.9% of the hirudin group (p =
0.06).19
A meta-analysis of the GUSTO IIb and TIMI 9B
trials showed that hirudin was more effective than
heparin at achieving and maintaining the target aPTT
range. Major bleeding could be reduced by careful
adjustment of both hirudin and heparin. However, there
was no difference in mortality in heparin- versus
hirudin-treated patients. There was a slight reduction
(14%) of reinfarction by 30 days in patients treated with
hirudin.20 The evidence suggests that, in the clinically
acceptable dose range, UFH and hirudin are equivalent
antithrombin strategies in patients with an ACS.
Hirulog has been evaluated as adjunctive therapy
to SK for ST-segment-elevation MI by several
investigators. An unusual dose response was observed
during analysis of the Hirulog Early Reperfusion/
Occlusion (HERO) study and a trial from the Montreal
Heart Institute. Lidon et al found that low-dose hirulog
(0.5 mg/kg/hr) produced an 85% rate of TIMI-3 flow21

at 90 minutes, while high-dose (1 mg/kg/hr) produced
a 61% rate of TIMI-3 flow.22 The notion that a low dose
of a direct thrombin inhibitor might be more effective
than a high dose has been hypothesized as being due to
the "thrombin paradox". This states that low doses of
antithrombins allow sufficient thrombin activity to
persist, leading to stimulation of the inhibitory
thrombomodulin and protein C pathway. However, the
HERO trial reported a TIMI-3 flow rate of 56% after
90-120 minutes in patients receiving high-dose hirulog
(0.5 mg/kg/hr) compared with 49% in patients receiving
low-dose hirulog (0.25 mg/kg/hr). 23 One of the
hypotheses put forward by the HERO investigators is
that the direct antithrombins must be administered prior
to initiation of thrombolytic therapy to maximise the
degree of inhibition of thrombin activity.
Dose-ranging phase-II angiographic trials have
also been performed with efegatran (Promotion of
Reperfusion in Myocardial Infarction [PRIME]23 and
[ESCALAT] studies)24 and agatroban (Argatroban in
Myocardial Infarction [ARGAMI]).25 Despite a sound
theoretical basis for anticipating improvements in the
rate of TIMI-3 flow when these direct antithrombins
were compared with UFH, either no improvement was
seen or only slightly higher rates of TIMI-3 flow were
observed. Although initially promising, no additional
benefits of direct antithrombin are seen in ST-segmentelevation MI.

Trials of direct antithrombins in
UA/NQWMI
The direct antithrombin inogatran has been
evaluated in the Thrombin Inhibition in Myocardial
Infarction (TRIM) study.10 A total of 1,209 patients with
UA received a 72-hour treatment with a low, medium
or high dose of inogatran or UFH. Although a dose-

Table 1. Hirudin vs. heparin for acute myocardial infarction
Rx window
Lytic
Heparin
Hirudin
bolus (mg/kg)
infusion (mg/kg/h)
aPTT target

113

TIMI 9A
12 h
tPA, SK
1000 U/h <80 kg
1300 U/h >80 kg

GUSTO IIa
12 h
tPA, SK
1000 U/h <80kg
1300 U/h >80kg

HIT-III
6h
tPA
15 U/kg/h

0.6
0.2
60-90 sec

0.6
0.2
60-90 sec

0.4
0.15
2.0-3.5 x Control
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dependent prolongation of the aPTT with a greater
stability of the anticoagulant effect compared with UFH
was observed in inogatran-treated patients, the primary
endpoint of death, recurrent MI, and refractory or
recurrent ischaemia was not reduced by inogatran.
The Organization to Assess Strategies for
Ischemic Syndromes (OASIS) pilot study compared
UFH with low-dose hirudin (bolus 0.2 mg/kg; infusion
0.1 mg/kg/hr) or medium-dose hirudin (bolus 0.4 mg/
kg; infusion 0.15 mg/kg/hr) for 72 hours in 909 patients
with UA or suspected acute MI without ST-elevation.26
The aPTT was monitored every 6-8 hours and was
maintained between 60-100 seconds. The medium-dose
hirudin group had a significant reduction in the risk of
cardiovascular death, MI, or refractory ischaemia at 7
days. As this trial was only moderate in size, a larger
OASIS-2 trial was conducted to extend the pilot study
results and investigated whether hirudin is superior to
UFH in reducing the risk of cardiovascular death or MI
at 7 days (primary outcome) and the composite of
cardiovascular death, MI, or refractory angina at 7 days
(secondary outcome). Patients were randomised to
receive UFH (5000 units bolus then 15 units/kg/hr; n =
5058) or hirudin (0.4 mg/kg bolus then 0.15 mg/kg/hr;
n = 5083) for 72 hours. There were no significant
differences among the treatment groups for the primary
outcome (3.6% in the hirudin group and 4.2% in the
UFH group; p = 0.077). The secondary outcome was
significantly reduced in the hirudin group compared
with the UFH group (5.6% vs 6.7% respectively; p =
0.0125). There was an excess of major bleeding

requiring transfusion with hirudin (1.2% vs 0.7% with
UFH; p = 0.01), although there was no difference in
life-threatening episodes (20 in each group) or strokes
(14 in each group).27 The data suggest that hirudin is
superior to UFH in reducing cardiovascular death, MI,
or refractory angina in patients with non-ST-elevation
ACS but at a cost of increased bleeding complications.

Low-molecular-weight heparins
LMWH preparations are produced by controlled
enzymatic or chemical depolymerization of UFH to
yield chains with a mean molecular weight of 5000.5
Both UFH and LMWHs exert their anticoagulant effect
by activating AT-III, mediated through binding of a
pentasaccharide sequence. Figure 4 illustrates that a
critical length of 18 saccharides is required to form the
ternary complex consisting of a haparin fragment, ATIII, and thrombin. In addition to the pentasaccharide
sequence discussed above that is critical for attachment
of a heparin fragment to AT-III, an additional 13
saccharide residues are necessary to allow the heparin
fragment to simultaneously attach itself to the heparinbinding domain of thrombin, thus creating the ternary
complex.
Short-chain or LMWH fragments of less than 18
saccharides retain the critical pentasaccharide sequence
but are of insufficient length to permit attachment to
the heparin-binding domain of thrombin, and therefore
thrombin is not inhibited by such short-chain fragments.

LMWH

Long Chain

Short Chain

Figure 4. Mechanism of action of low-molecular-weight
heparins. LMWHs consist of varying mixtures of short and
long chain components (presence and absence of ≥ 18
saccharide units, respectively), capable of different degree
of factor IIa and Xa inhibition. A higher percentage of short
chain components enables a more potent anti-Xa activity.
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However, only the critical pentasaccharide sequence is
required for binding to AT-III and inhibiting factor Xa.
By creating a mixture of short-chain and long-chain
heparin fragments, preparations of varying anti-Xa:antiIIa activity can be developed (table 2). Higher anti-Xa
activity is important because of the multiplier effect
such that a single molecule of factor Xa leads to the
production of many molecules of thrombin.
Decreased binding to plasma proteins, endothelial
cells and macrophages explains the pharmacokinetic
differences between UFH and LMWHs. LMWHs have
a better bioavailability, longer half-life, and doseindependent clearance. Thus, a more reliable, stable
anticoagulant effect is produced. Laboratory monitoring
is unnecessary except in patients with renal insufficiency
and possibly those with a body weight of less than 50
kg or more than 80 kg. 5 Together with the ease of
administration by the subcutaneous route, a decreased
sensitivity to inactivation by platelet factor IV and lower
rates of thrombocytopenia and HITS, LMWHs are
clinically attractive alternatives to UFH.

Trials of LMWHs in UA/NQWMI
Gurfinkel and colleagues28 compared placebo
treatment, UFH, and the LWMH nadroparin in 219
patients with UA who were also treated with aspirin. In
this single-blind study, patients were randomised to
receive aspirin (200 mg/day), aspirin plus UFH (5,000
units bolus IV, followed by IV infusion of 400 units/
kg/day, with a target APTT of 2 times control), or aspirin
plus nadroparin (214 IU/kg SC twice daily). Treatment
was continued for 5-7 days (until hospital discharge) or
until the occurrence of a primary endpoint (recurrent
angina, acute MI, need for urgent intervention, major
bleeding, or death). The study was terminated
prematurely on a recommendation from the Data Safety
Monitoring Committee. Combination therapy with

aspirin plus nadroparin significantly reduced the
incidence of a primary endpoint event from 59% in the
aspirin group and 63% in the aspirin plus UFH group
to 22% in the aspirin plus nadroparin group (p< 0.0001
for the comparisons of the nadroparin group with each
of the other 2 groups). Bleeding complications were
rare and were largely related to cardiac catheterisation
access sites.
Following the Gurfinkel study, two larger trials
examining the LMWH dalteparin (Fragmin) were
reported. The Fragmin During Instability in Coronary
Artery Disease (FRISC) 29 trial tested whether SC
administration of dalteparin would reduce ischemic
events during the acute in-hospital period following an
episode of UA/NQWMI. A secondary goal was to
determine whether long-term anticoagulation therapy
would provide additional benefit compared with
anticoagulation restricted to the acute phase (the first
few days following hospitalisation). Patients presentng
within 72 hours of the onset of UA/NQWMI were
randomly assigned to receive either dalteparin (120 IU/
kg SC twice daily for 6 days followed by daily SC
injections of 7,500 IU for an additional 35-45 days; n =
746) or placebo (n = 760). All patients received aspirin.
Dalteparin-treated patients had a 63% reduction in death
and nonfatal MI at the 6-day analysis (4.8% in the
placebo group compared with 1.8% in the dalteparin
group, p = 0.001). With longer-term follow-up, event
rates for the two groups began to converge, and a nonsignificant trend toward improved outcome was
observed in the dalteparin group by 40 days (10.7% for
the placebo group compared with 8.0% in the dalteparin
group, p = 0.07). By 150 days, there was no significant
difference between the two groups.
The Fragmin in Unstable Coronary Artery
Disease (FRIC)30 study compared dalteparin with UFH
in patients with UA/NQWMI presenting within 72 hours
of an episode of ischaemic chest pain. During the acute
phase (the first 6 days following hospitalisation),

Table 2. Low-molecular-weight heparin preparations
Preparation

Method of Preparation

dalteparin (Fragmin)
enoxaparin (Clexane)

nitrous acid depolymerization
benzylation and alkaine
depolymerization
nitrous acid depolymerization
nitrous acid depolymerization,
chromatographic purification
heparinase digestion

nadroparin (Fraxiparine)
reviparin (Clivarine)
tinzaparin (Innohep)
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Mean
Molecular
Weight (Dalton)
6000

Anti-Xa:
Anti-IIa
Activity*
2.7

4200
4500

3.8
3.6

4000
4500

3.5
1.9
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patients received either twice-daily SC dalteparin or IV
UFH for the first 48 hours. During the chronic phase,
SC dalteparin or placebo was continued until day 45.
All patients received aspirin throughout the course of
the study. The occurrence of the composite outcome of
death, MI, or recurrent angina was similar for the UFH
and dalteparin groups during the 6-day acute period
(7.6% vs. 9.3% for the UFH and dalteparin groups
respectively). Similarly, after 45 days, the incidence of
the composite endpoint was 12.3% for both groups.
The Efficacy and Safety of Subcutaneous
Enoxaparin in Non-Q-wave Coronary Events
(ESSENCE)31 trial examined the use of enoxaparin in
UA/NQWMI. This large, multicentre, double-blind trial
randomised 3,171 patients within 24 hours of onset of
ischaemic chest pain to receive either twice-daily SC
enoxaparin (1 mg/kg), or IV UFH during the acute
period (2-8 days) following hospitalisation. The primary
endpoint was a composite of death, MI, or recurrent
angina within 14 days of hospitalisation. The median
duration of treatment with the study drug was 2.6 days.
The rate of endpoint events was significantly reduced
in the enoxaparin group compared with the UFH group
(16.6% vs. 19.8%, p = 0.019). The enoxaparin group
continued to have fewer events compared with the UFH
group through 30 days, at which time a primary endpoint
event had occurred in 19.8% of the enoxaparin group
and 23.3% of the UFH group (p = 0.016). The incidence
of major bleeding complications was similar between
the two groups.
The FRAX.I.S study compared the efficacy and
safety of the treatment with UFH versus a 6-day or a
14-day treatment with nadroparin in patients with UA
or NQWMI. 32 Altogether 3,468 patients presenting
within 2 days of the qualifying episode of ischaemic
pain were randomized to one of the 3 groups: UFH
5,000 IU bolus IV followed by infusion for 6 days,
nadroparin bolus followed by SC 87 IU/kg twice daily
for 6 days in the short term group, and twice daily for
14 days in the longer term group. The primary endpoint
was a composite of cardiovascular death, MI, or
refractory or recurrent angina at 2 weeks. There was no
significant difference in the primary endpoint between
the three groups: 18.1% for the UFH group, 17.8% for
the 6-day and 20% for the 2-week nadroparin groups.
Major haemorrhages occurred more often in the long
term nadroparin group (3.5%) than the UFH group
(1.5%) and the short term nadroparin group (1.6%).
The TIMI 11B trial assessed the effect of
enoxaparin compared to UFH on death and cardiac
ischaemic events in the management of UA/
NQWMI.33 Eligible patients (presenting within 24 hours
of onset of ischaemic chest pain; n = 3,910) were treated
J HK Coll Cardiol, Vol 7

with aspirin and randomised to double-blind treatment
with either UFH (70 units IV bolus followed by 15 units/
kg/hr to maintain the aPTT 1.5-2.5 times control) for at
least 3 days or enoxaparin (30 mg IV bolus followed
by 1 mg/kg SC twice daily) for an average of 4.6 days.
Following treatment in the acute phase, eligible patients
proceeded to the chronic phase and received enoxaparin
or placebo up to day 43 (enoxaparin 40 mg SC daily for
those < 65 kg; 60 mg SC daily for those ≥ 65 kg). The
primary endpoint of all-cause mortality/recurrent MI/
recurrent ischaemia prompting urgent revascularisation
at day 14 was reduced from 16.6% in the UFH group to
14.2% in the enoxaparin group (p = 0.03). All individual
elements of the composite endpoint were reduced in
the enoxaparin group. There was no increase in the rate
of either spontaneous or instrumented major
haemorrhage. The initial benefit of enoxaparin therapy
was maintained in the chronic phase (primary endpoint
event rate of 19.7% for the placebo group vs. 17.3% for
the enoxaparin group, p < 0.05) but there was no
additional relative decrease in events. There was an
increase in the rate of major haemorrhage (both
spontaneous and instrumented; placebo group 1.5% vs.
enoxaparin group 2.9%, p < 0.05). In a meta-analysis
of TIMI 11B and ESSENCE, enoxaparin was associated
with a significant 20% reduction in the incidence of
death and MI compared with UFH.

Conclusions
It seems likely that UFH will be used less
frequently in the future when the role of newer
antithrombin agents and LMWHs is clarified by
additional research. Based on the evidence from clinical
trials to date, the direct antithrombins provide a more
consistent anticoagulant effect compared with UFH.
However, the therapeutic window appears to be much
narrower than originally appreciated. Within the range
of clinically acceptable doses to minimise bleeding
complications, the direct antithrombins have similar
efficacy to UFH in ST-elevation acute MI. Although
demonstrated to be superior to UFH in reducing
ischaemic cardiac events in non-ST-elevation ACS,
hirudin produces more major bleeding complications
than UFH. Considering the efficacy, safety, and ease of
administration, hirudin is a less attractive alternative
compared with LMWHs to be used in UA/NQWMI.
Despite sharing many pharmacologic similarities,
LMWHs vary in significant aspects. It is important to
consider each drug individually rather than as a member
of a class of interchangeable compounds. The varying
efficacy of LMWHs in clinical trials might reflect
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differing anti-Xa:anti-IIa ratios. Having an in-vitro antiXa:anti-IIa ratio of 3.8, enoxaparin has been shown in
two large randomised trials to reduce ischaemic events
following UA/NQWMI. Although the evidence is less
strong, nadroparin, which has an anti-Xa:anti-IIa ratio
of 3.6, also appears to be superior to UFH in this setting.
On the other hand, dalteparin appears to be less effective,
possibly related to an anti-Xa:anti-IIa ratio of 2.2 only.
However, it is also possible that the lack of sustained
effect of dalteparin in the FRISC and FRIC trials was
due to the long patient enrollment period after the
episode of qualifying chest pain (72 hours in both
studies), in contrast to a 24-hour enrollment period in
most other studies.
It is anticipated that LMWHs will be used more
frequently in patients with ACS and UFH may be
replaced as the role of LMWHs is further defined by
ongoing clinical trials.
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